Skip to main content

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Active, not recruiting · Phase 1, Phase 2 · NCT03785249

Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease

At a glance

Research payments reported, 2025
$5.9M
U.S. investigators named
77
Sites paid
51
Planned or actual enrollment
731

About the trial

Sponsor
Mirati Therapeutics Inc.
Tested
MRTX849 (drug), Pembrolizumab (drug), Cetuximab (drug), Afatinib (drug)
Dates
Started 2019-01-15; completion 2026-12-31
Results posted
Not yet

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

From ClinicalTrials.gov, last updated 2026-07-29. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Mirati Therapeutics, Inc. reported $5.9M in research payments for this study in 2025 (111 payments).

Products named: Krazati

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.